Terms: = Skin cancer AND CDH1, uvomorulin, 999, P12830, ENSG00000039068, CDHE, Arc-1, UVO, LCAM, CD324, ECAD AND Treatment
30 results:
1. Factors Affecting Recurrence and Survival for Patients with High-Risk Stage II Melanoma.
Dedeilia A; Lwin T; Li S; Tarantino G; Tunsiricharoengul S; Lawless A; Sharova T; Liu D; Boland GM; Cohen S
Ann Surg Oncol; 2024 Apr; 31(4):2713-2726. PubMed ID: 38158497
[TBL] [Abstract] [Full Text] [Related]
2.
Romano B; Maresca DC; Somma F; Ahmadi P; Putra MY; Rahmawati SI; Chianese G; Formisano C; Ianaro A; Ercolano G
Mar Drugs; 2023 Jun; 21(7):. PubMed ID: 37504902
[TBL] [Abstract] [Full Text] [Related]
3. Clinical benefit of switching from paclitaxel to docetaxel or vice versa in cutaneous angiosarcoma patients resistant to first taxane chemotherapy.
Yonekura S; Endo Y; Fujii H; Ishikawa M; Egawa G; Kabashima K
J Dermatol; 2023 Nov; 50(11):1493-1496. PubMed ID: 37400887
[TBL] [Abstract] [Full Text] [Related]
4. Anatomic Locations of Procedurally Treated Keratinocyte Carcinomas in the US Medicare Population.
Navsaria LJ; Li Y; Tripathy S; Cox ML; Hinkston CL; Margolis DJ; Wehner MR
JAMA Dermatol; 2023 Jun; 159(6):643-647. PubMed ID: 37074701
[TBL] [Abstract] [Full Text] [Related]
5. Exosomal miR-22-3p from Mesenchymal Stem Cells Inhibits the Epithelial-Mesenchymal Transition (EMT) of Melanoma Cells by Regulating
Chen Y; Fang Y; Li L; Luo H; Cao T; Tu B
Front Biosci (Landmark Ed); 2022 Sep; 27(9):275. PubMed ID: 36224027
[TBL] [Abstract] [Full Text] [Related]
6. Predicting recurrence in patients with sentinel node-negative melanoma: validation of the EORTC nomogram using population-based data.
El Sharouni MA; Ahmed T; Witkamp AJ; Sigurdsson V; van Gils CH; Nieweg OE; Scolyer RA; Thompson JF; van Diest PJ; Lo SN
Br J Surg; 2021 May; 108(5):550-553. PubMed ID: 34043770
[TBL] [Abstract] [Full Text] [Related]
7. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma.
Owen CN; Bai X; Quah T; Lo SN; Allayous C; Callaghan S; Martínez-Vila C; Wallace R; Bhave P; Reijers ILM; Thompson N; Vanella V; Gerard CL; Aspeslagh S; Labianca A; Khattak A; Mandala M; Xu W; Neyns B; Michielin O; Blank CU; Welsh SJ; Haydon A; Sandhu S; Mangana J; McQuade JL; Ascierto PA; Zimmer L; Johnson DB; Arance A; Lorigan P; Lebbé C; Carlino MS; Sullivan RJ; Long GV; Menzies AM
Ann Oncol; 2021 Jul; 32(7):917-925. PubMed ID: 33798657
[TBL] [Abstract] [Full Text] [Related]
8. Dosimetric impact and modeling of prone breast positioning device and couch structures.
Lau A; Salerno KE; Ma T; Wang IZ
Med Dosim; 2021 Autumn; 46(3):219-228. PubMed ID: 33483223
[TBL] [Abstract] [Full Text] [Related]
9. Correlation study between the magnetic resonance imaging features of breast cancer and expression of immune molecular subtypes.
Long N; Ran C; Sun J; Hao CJ; Sui YB; Li J; Shi YX; Zou ZX; Qu YH
Eur Rev Med Pharmacol Sci; 2020 Nov; 24(22):11518-11527. PubMed ID: 33275218
[TBL] [Abstract] [Full Text] [Related]
10. Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/Sézary syndrome than quantification of CD26- or CD7- CD4+ T-cells.
Lyapichev KA; Bah I; Huen A; Duvic M; Routbort MJ; Wang W; Jorgensen JL; Medeiros LJ; Vega F; Craig FE; Wang SA
Cytometry B Clin Cytom; 2021 Mar; 100(2):183-191. PubMed ID: 32667737
[TBL] [Abstract] [Full Text] [Related]
11. Targeted next-generation sequencing of matched localized and metastatic primary high-risk SCCs identifies driver and co-occurring mutations and novel therapeutic targets.
Lobl MB; Clarey D; Higgins S; Sutton A; Hansen L; Wysong A
J Dermatol Sci; 2020 Jul; 99(1):30-43. PubMed ID: 32595073
[TBL] [Abstract] [Full Text] [Related]
12. The prognostic role of BRAF and WNT pathways activation in kinase inhibitors-naïve clinical stage III cutaneous melanoma.
Kowalik A; Jurkowska M; Mierzejewska E; Ługowska I; Gos A; Szumera-Ciećkiewicz A; Zięba S; Koseła-Paterczyk H; van der Oord J; Dębiec-Rychter M; Szamotulska K; Siedlecki J; Rutkowski P
Melanoma Res; 2020 Aug; 30(4):348-357. PubMed ID: 32073511
[TBL] [Abstract] [Full Text] [Related]
13. An evaluation of techniques used in superficial radiotherapy for non-melanoma skin cancer to replicate the planned treatment area: A prospective study.
Vassiliou M; Callender J; Manning-Stanley AS
Radiography (Lond); 2019 Nov; 25(4):280-287. PubMed ID: 31582233
[TBL] [Abstract] [Full Text] [Related]
14. Profiles of brain metastases: Prioritization of therapeutic targets.
Ferguson SD; Zheng S; Xiu J; Zhou S; Khasraw M; Brastianos PK; Kesari S; Hu J; Rudnick J; Salacz ME; Piccioni D; Huang S; Davies MA; Glitza IC; Heymach JV; Zhang J; Ibrahim NK; DeGroot JF; McCarty J; O'Brien BJ; Sawaya R; Verhaak RGW; Reddy SK; Priebe W; Gatalica Z; Spetzler D; Heimberger AB
Int J Cancer; 2018 Dec; 143(11):3019-3026. PubMed ID: 29923182
[TBL] [Abstract] [Full Text] [Related]
15. USF1 prompt melanoma through upregulating TGF-β signaling pathway.
Ren YQ; Li QH; Liu LB
Eur Rev Med Pharmacol Sci; 2016 Sep; 20(17):3592-8. PubMed ID: 27649659
[TBL] [Abstract] [Full Text] [Related]
16. Transscleral resection without hypotensive anaesthesia vs iodine-125 plaque brachytherapy in the treatment of choroidal melanoma.
Caminal JM; Padrón-Pérez N; Arias L; Masuet-Aumatell C; Gutiérrez C; Piulats JM; Pera J; Català J; Rubio MJ; Arruga J
Eye (Lond); 2016 Jun; 30(6):833-42. PubMed ID: 27034202
[TBL] [Abstract] [Full Text] [Related]
17. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.
Price TJ; Peeters M; Kim TW; Li J; Cascinu S; Ruff P; Suresh AS; Thomas A; Tjulandin S; Zhang K; Murugappan S; Sidhu R
Lancet Oncol; 2014 May; 15(6):569-79. PubMed ID: 24739896
[TBL] [Abstract] [Full Text] [Related]
18. Initial metastatic kinetics is the best prognostic indicator in stage IV metastatic melanoma.
Gaudy-Marqueste C; Archier E; Grob A; Durieux O; Loundou A; Richard MA; Grob JJ
Eur J Cancer; 2014 Apr; 50(6):1120-4. PubMed ID: 24440089
[TBL] [Abstract] [Full Text] [Related]
19. Molecular and genetic diversity in the metastatic process of melanoma.
Harbst K; Lauss M; Cirenajwis H; Winter C; Howlin J; Törngren T; Kvist A; Nodin B; Olsson E; Häkkinen J; Jirström K; Staaf J; Lundgren L; Olsson H; Ingvar C; Gruvberger-Saal SK; Saal LH; Jönsson G
J Pathol; 2014 May; 233(1):39-50. PubMed ID: 24399611
[TBL] [Abstract] [Full Text] [Related]
20. The burden of metastatic melanoma: treatment patterns, healthcare use (utilization), and costs.
Reyes C; DaCosta Byfield S; Linke R; Satram-Hoang S; Teitelbaum AH
Melanoma Res; 2013 Apr; 23(2):159-66. PubMed ID: 23370422
[TBL] [Abstract] [Full Text] [Related]
[Next]
